Indivior Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for SUBOXONE® (buprenorphine and naloxone) Sublingual Film
June 18, 2019 | PDF Version
New Data from the RECOVER™ Study Reports on Abstinence, Drug Craving and Psychosocial Outcomes in People with Opioid Use Disorder following Transition from a Clinical Trial to the Real-World Setting
June 17, 2019 | PDF Version
June 4, 2019 | PDF Version
May 16, 2019 | PDF Version
Updates on the Department of Justice Action
Get updates and information on Indivior’s ongoing response to the recent action by the U.S. Department of Justice and learn about the company’s unwavering commitment to patients, doctors, and communities fighting opioid addiction.
See more >
Click on the headings to view online or download a presentation:
- See more
View Indivior filings with the Regulatory News Service on regulatory and non-regulatory updates.
View Indivior Annual Reports